{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:04:35Z","timestamp":1789502675696,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The publication of our recent randomized controlled trial (RCT) showing that vitamin D could protect the \u03b2-cells during the honeymoon phase of type 1 diabetes (T1D) has led to calls for guidance for vitamin D supplementation during the critical phase of type 1 diabetes. Prolonging the partial clinical remission (PR) phase of TID improves glycemic control and reduces long-term complications of T1D. This RCT randomized 36 children and adolescents to either receive vitamin D<jats:sub>2<\/jats:sub> (ergocalciferol, given as 50,000 international units per week for 2 months and then every other week for 10 months) or a placebo. The results showed that vitamin D significantly decreased the temporal rise in both hemoglobin A1c at a mean rate of changes of 0.14% every 3 months versus 0.46% every 3 months for the placebo group (p=0.044); and in the functional marker of PR, the insulin-dose adjusted A1c at a mean rate of change of 0.30% every 3 months versus 0.77% every 3 months for the placebo group, (p=0.015). We recommend a baseline estimation of 25(OH)D concentration at the time of diagnosis of T1D, and to begin vitamin D supplementation if serum 25(OH)D concentration is &amp;lt;30 ng\/mL, to maintain serum 25(OH)D concentrations between 30-60 ng\/mL. If serum 25(OH)D concentration is &amp;gt;30 ng\/mL, monitor vitamin D status with serial 25(OH)D estimations; and initiate vitamin D supplementation if serum 25(OH)D concentrations drop to &amp;lt;30 ng\/mL. Continue vitamin D supplementation for at least one year to ensure optimal benefit from vitamin D supplementation during the partial clinical remission phase of type 1 diabetes.<\/jats:p>","DOI":"10.3389\/fendo.2022.974196","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:07:54Z","timestamp":1660802874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Guidance for high-dose vitamin D supplementation for prolonging the honeymoon phase in children and adolescents with new-onset type 1 diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Benjamin Udoka","family":"Nwosu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","volume-title":"CDC National diabetes statistics report","year":"2020"},{"key":"B2","volume-title":"Statistics about diabetes","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(18)30024-2","article-title":"Type 1 diabetes","volume":"391","author":"Barnett","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.suppl_2.s32","article-title":"Natural history of beta-cell function in type 1 diabetes","author":"Sherry","year":"2005","journal-title":"Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3067-x","article-title":"The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells","volume":"57","author":"Oram","year":"2014","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127397","article-title":"Residual beta cell function and monogenic variants in long-duration type 1 diabetes patients","volume":"129","author":"Yu","year":"2019","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.10.055","article-title":"Deoxyandrographolide promotes glucose uptake through glucose transporter-4 translocation to plasma membrane in L6 myotubes and exerts antihyperglycemic effect in vivo","volume":"768","author":"Arha","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2012.164","article-title":"Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual beta-cell function in new-onset type 1 diabetes mellitus","volume":"166","author":"Gabbay","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134057","article-title":"High residual c-peptide likely contributes to glycemic control in type 1 diabetes","volume":"130","author":"Rickels","year":"2020","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/ijms21062103","article-title":"Immunotherapy strategies for the prevention and treatment of distinct stages of type 1 diabetes: An overview","volume":"21","author":"Rapini","year":"2020","journal-title":"Int J Mol Sci 21"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1727885","article-title":"CTLA4-ig (Abatacept): A promising investigational drug for use in type 1 diabetes","volume":"29","author":"Rachid","year":"2020","journal-title":"Expert Opin investigational Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.101510","article-title":"Decreased interleukin-35 levels and CD4(+)EBI3(+) T cells in patients with type 1 diabetes and the effects of the antibody against CD20 (Rituximab)","volume":"17","author":"Ouyang","year":"2021","journal-title":"Arch Med Science: AMS"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2015-0088","article-title":"Effect of 6-months\u2019 vitamin d supplementation on residual beta cell function in children with type 1 diabetes: A case control interventional study","author":"Mishra","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0274","article-title":"Why do so many trials of vitamin d supplementation fail","volume":"9","author":"Boucher","year":"2020","journal-title":"Endocrine connections"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1559","article-title":"Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term","volume":"63","author":"Takiishi","year":"2014","journal-title":"Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-870578","article-title":"Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes","volume":"37","author":"Pozzilli","year":"2005","journal-title":"Horm Metab Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"bvab179","DOI":"10.1210\/jendso\/bvab179","article-title":"Ergocalciferol in new-onset type 1 diabetes: A randomized controlled trial","volume":"6","author":"Nwosu","year":"2022","journal-title":"J Endocrine Soc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12208","article-title":"Partial remission definition: Validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes","volume":"15","author":"Max Andersen","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1987","article-title":"New definition for the partial remission period in children and adolescents with type 1 diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12734","article-title":"ISPAD clinical practice consensus guidelines 2018: Stages of type 1 diabetes in children and adolescents","author":"Couper","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000479030","article-title":"Remission phase in paediatric type 1 diabetes: New understanding and emerging biomarkers","volume":"88","author":"Fonolleda","year":"2017","journal-title":"Hormone Res paediatrics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2010.04.001","article-title":"Modulator of the immune system","volume":"10","author":"Baeke","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.4.2280","article-title":"A vitamin d analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development","volume":"173","author":"Giarratana","year":"2004","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.02.013","article-title":"Vitamin d and diabetes","volume":"39","author":"Takiishi","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/nu12051248","article-title":"Vitamin d\u2019s effect on immune function","volume":"12","author":"Martens","year":"2020","journal-title":"Nutrients"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176860","article-title":"A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes","volume":"12","author":"Marino","year":"2017","journal-title":"PloS One"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.974196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:07:58Z","timestamp":1660802878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.974196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":28,"alternative-id":["10.3389\/fendo.2022.974196"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.974196","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"974196"}}